Latest Virus-like particle Stories
QUEBEC CITY, April 13 /PRNewswire/ - Medicago Inc.
QUEBEC CITY, April 6 /PRNewswire-FirstCall/ - Medicago Inc.
ROCKVILLE, Md., April 5, 2011 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX) announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today.
ROCKVILLE, Md., March 22, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr.
APPROVED FOR PUBLIC RELEASE, DISTRIBUTION UNLIMITED RALEIGH AND QUEBEC CITY, March 15 /PRNewswire-FirstCall/ - Medicago USA Inc., a wholly owned subsidiary of Medicago Inc.
QUEBEC CITY, March 14 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr.
ROCKVILLE, Md., March 3, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Maryland State Governor Martin O'Malley will visit the company's headquarters in Rockville, Maryland, on Monday, March 7, to celebrate the recently announced contract valued at up to $179 million.
ROCKVILLE, Md., March 1, 2011 /PRNewswire/ -- Novavax, Inc.
ROCKVILLE, Md., Feb. 28, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today an agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to LG Life Sciences, Ltd. (LGLS).
ROCKVILLE, Md., Feb. 18, 2011 /PRNewswire/ -- Novavax, Inc.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.